Literature DB >> 10388024

The Role of CA-125 in the Management of Ovarian Cancer.

.   

Abstract

Over more than a decade of clinical use, CA-125 has proven itself to be one of the most useful tumor markers in cancer medicine. The major clinical utility of this serum marker is in following the clinical course of women with known ovarian cancer. Other potential uses of CA-125 include the evaluation of the effectiveness of new antineoplastic agents in this malignancy, and in the modification of treatment strategies in individuals whose CA-125 levels fail to decline at an acceptable rate following the institution of therapy. At the present time, the use of CA-125 as a method to screen for ovarian cancer should be considered investigational.

Entities:  

Year:  1997        PMID： 10388024

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


  16 in total

Review 1.  Limitations to the use of the CA-125 antigen level in ovarian cancer.

Authors:  Maurie Markman
Journal:  Curr Oncol Rep       Date:  2003-07       Impact factor: 5.075

2.  HE4, Ca125 and ROMA algorithm for differential diagnosis between benign gynaecological diseases and ovarian cancer.

Authors:  Blanca Ortiz-Muñoz; Eduardo Aznar-Oroval; Ana García García; Amparo Covisa Peris; Pilar Perez Ballestero; Marina Sanchez Yepes; Tomás Garcia Lozano; Carmen Illueca Ballester; Enrique García Garcia
Journal:  Tumour Biol       Date:  2014-04-27

Review 3.  Proteomics in cancer screening and management in gynecologic cancer.

Authors:  Wei Hu; Weiguo Wu; Ryuji Kobayashi; John J Kavanagh
Journal:  Curr Oncol Rep       Date:  2004-11       Impact factor: 5.075

4.  Effects of personal characteristics on serum CA125, mesothelin, and HE4 levels in healthy postmenopausal women at high-risk for ovarian cancer.

Authors:  Kimberly A Lowe; Chirag Shah; Erin Wallace; Garnet Anderson; Pamela Paley; Martin McIntosh; M Robyn Andersen; Nathalie Scholler; Lindsay Bergan; Jason Thorpe; Nicole Urban; Charles W Drescher
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-09       Impact factor: 4.254

5.  Human epididymis protein 4 reference limits and natural variation in a Nordic reference population.

Authors:  Nils Bolstad; Miriam Øijordsbakken; Kjell Nustad; Johan Bjerner
Journal:  Tumour Biol       Date:  2011-11-22

6.  Thrombopoietin: a novel candidate tumor marker for the diagnosis of ovarian cancer.

Authors:  Timucin Mermer; Mustafa Cosan Terek; Burak Zeybek; Ahmet Mete Ergenoglu; Ahmet Ozgur Yeniel; Aydın Ozsaran; Osman Zekioglu
Journal:  J Gynecol Oncol       Date:  2012-04-03       Impact factor: 4.401

7.  Peritoneal tuberculosis mimicking advanced ovarian carcinoma: an important differential diagnosis to consider.

Authors:  Maria A Gosein; Dylan Narinesingh; Gordon V Narayansingh; Nazreen A Bhim; Pearse A Sylvester
Journal:  BMC Res Notes       Date:  2013-03-09

8.  Potential tumor biomarkers identified in ovarian cyst fluid by quantitative proteomic analysis, iTRAQ.

Authors:  Björg Kristjansdottir; Kristina Levan; Karolina Partheen; Elisabet Carlsohn; Karin Sundfeldt
Journal:  Clin Proteomics       Date:  2013-04-04       Impact factor: 3.988

9.  Serum folate receptor alpha, mesothelin and megakaryocyte potentiating factor in ovarian cancer: association to disease stage and grade and comparison to CA125 and HE4.

Authors:  Daniel J O'Shannessy; Elizabeth B Somers; Leslie M Palmer; Robert P Thiel; Pankaj Oberoi; Ryan Heath; Lisa Marcucci
Journal:  J Ovarian Res       Date:  2013-04-17       Impact factor: 4.234

10.  Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts.

Authors:  K Huhtinen; P Suvitie; J Hiissa; J Junnila; J Huvila; H Kujari; M Setälä; P Härkki; J Jalkanen; J Fraser; J Mäkinen; A Auranen; M Poutanen; A Perheentupa
Journal:  Br J Cancer       Date:  2009-03-31       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.